Oxytocin in survivors of childhood-onset craniopharyngioma

[en] Quality of survival of childhood-onset cranio- pharyngioma patients is frequently impaired by hypotha- lamic involvement or surgical lesions sequelae such as obesity and neuropsychological deficits. Oxytocin, a pep- tide hormone produced in the hypothalamus and secreted by posterior pituitary gland, plays a major role in regula- tion of behavior and body composition. In a cross- sectional study, oxytocin saliva concentrations were ana- lyzed in 34 long-term craniopharyngioma survivors with and without hypothalamic involvement or treatment- related damage, recruited in the German Childhood Cra- niopharyngioma Registry, and in 73 healthy controls, attending the Craniopharyngioma Support Group Meeting 2014. Oxytocin was measured in saliva of craniophar- yngioma patients and controls before and after standar- dized breakfast and associations with gender, body mass index, hypothalamic involvement, diabetes insipidus, and irradiation were analyzed. Patients with preoperative hypothalamic involvement showed similar oxytocin levels compared to patients without hypothalamic involvement and controls. However, patients with surgical hypotha- lamic lesions grade 1 (anterior hypothalamic area) pre- sented with lower levels (p = 0.017) of oxytocin under fasting condition compared to patients with surgical lesion of posterior hypothalamic areas (grade 2) and patients without hypothalamic lesions (grade 0). Craniophar- yngioma patients’ changes in oxytocin levels before and after breakfast correlated (p = 0.02) with their body mass index. Craniopharyngioma patients continue to secrete oxytocin, especially when anterior hypothalamic areas are not involved or damaged, but oxytocin shows less varia- tion due to nutrition. Oxytocin supplementation should be explored as a therapeutic option in craniopharyngioma patients with hypothalamic obesity and/or behavioral pathologies due to lesions of specific anterior hypotha- lamic areas. Clinical trial number: KRANIOPHAR- YNGEOM 2000/2007(NCT00258453; NCT01272622).

Disciplines :

Neurology
Endocrinology, metabolism & nutrition

Author, co-author :

Daubenbüchel, Anna; Klinikum Oldenburg AöR, Germany > Pediatrics

Hoffmann, Anika; Klinikum Oldenburg AöR, Germany > Pediatrics

Eveslage, Maria; University of Münster, Germany > Institute of Bioatatistics and Clinical Research

Özyurt, Jale; University of Oldenburg, Germany > Biological Psychology

Lohle, Kristin; Klinikum Oldenburg AöR, Germany > Pediatrics

Reichel, Julia; Klinikum Oldenburg AöR, Germany > Pediatrics

Thiel, Christiane M.; University of Oldenburg, Germany > Research Center Neurosensory Science

Martens, Henri ; Université de Liège > Centre d'immunologie

Geenen, Vincent ; Université de Liège > Centre d'immunologie

Müller, Hermann L.; Klinikum Oldenburg AöR, Germany > Pediatrics

Language :

English

Title :

Oxytocin in survivors of childhood-onset craniopharyngioma

Publication date :

September 2016

Journal title :

Endocrine

ISSN :

1355-008X

eISSN :

1559-0100

Publisher :

Humana Press, Totowa, United States - New Jersey

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

German Childhood Cancer Foundation

Available on ORBi :

since 07 September 2016

Statistics

Number of views

296 (6 by ULiège)

Number of downloads

902 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

H.L. Muller, Craniopharyngioma. Endocr. Rev. 35(3), 513–543 (2014). doi:10.1210/er.2013-1115
H.L. Muller, Consequences of craniopharyngioma surgery in children. J. Clin. Endocrinol. Metab. 96(7), 1981–1991 (2011). doi:10.1210/jc.2011-0174
O.M. Dekkers, N.R. Biermasz, J.W. Smit, L.E. Groot, F. Roelfsema, J.A. Romijn, A.M. Pereira, Quality of life in treated adult craniopharyngioma patients. Eur. J. Endocrinol. 154(3), 483–489 (2006). doi:10.1530/eje.1.02114
A.S. Sterkenburg, A. Hoffmann, U. Gebhardt, M. Warmuth-Metz, A.M. Daubenbuchel, H.L. Muller, Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 17(7), 1029–1038 (2015). doi:10.1093/neuonc/nov044
A. Bereket, W. Kiess, R.H. Lustig, H.L. Muller, A.P. Goldstone, R. Weiss, Y. Yavuz, Z. Hochberg, Hypothalamic obesity in children. Obes. Rev. 13(9), 780–798 (2012). doi:10.1111/j.1467-789X.2012.01004.x
G. Zada, E.R. Laws, Surgical management of craniopharyngiomas in the pediatric population. Horm. Res. Paediatr 74(1), 62–66 (2010). doi:10.1159/000309349
H.L. Muller, Craniopharyngioma and hypothalamic injury: latest insights into consequent eating disorders and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 23(1), 81–89 (2016). doi:10.1097/MED.0000000000000214
A. Acevedo-Rodriguez, S.K. Mani, R.J. Handa, Oxytocin and estrogen receptor beta in the brain: an overview. Front. Endocrinol. (Lausanne) 6, 160 (2015). doi:10.3389/fendo.2015.00160
H.J. Lee, A.H. Macbeth, J.H. Pagani, W.S. Young 3rd, Oxytocin: the great facilitator of life. Prog. Neurobiol. 88(2), 127–151 (2009). doi:10.1016/j.pneurobio.2009.04.001
E. Frank, R. Landgraf, The vasopressin system--from antidiuresis to psychopathology. Eur. J. Pharmacol. 583(2-3), 226–242 (2008). doi:10.1016/j.ejphar.2007.11.063
E.A. Lawson, D.A. Marengi, R.L. DeSanti, T.M. Holmes, D.A. Schoenfeld, C.J. Tolley, Oxytocin reduces caloric intake in men. Obesity (Silver Spring) 23(5), 950–956 (2015). doi:10.1002/oby.21069
M. Olff, J.L. Frijling, L.D. Kubzansky, B. Bradley, M.A. Ellenbogen, C. Cardoso, J.A. Bartz, J.R. Yee, M. van Zuiden, The role of oxytocin in social bonding, stress regulation and mental health: an update on the moderating effects of context and interindividual differences. Psychoneuroendocrinology 38(9), 1883–1894 (2013). doi:10.1016/j.psyneuen.2013.06.019
H.E. Ross, L.J. Young, Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front. Neuroendocrinol. 30(4), 534–547 (2009). doi:10.1016/j.yfrne.2009.05.004
T.R. Insel, The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 65(6), 768–779 (2010). doi:10.1016/j.neuron.2010.03.005
P.S. Churchland, P. Winkielman, Modulating social behavior with oxytocin: how does it work? What does it mean? Horm. Behav. 61(3), 392–399 (2012). doi:10.1016/j.yhbeh.2011.12.003
M. Tauber, C. Mantoulan, P. Copet, J. Jauregui, G. Demeer, G. Diene, B. Roge, V. Laurier, V. Ehlinger, C. Arnaud, C. Molinas, D. Thuilleaux, Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients. Orphanet J. Rare Dis. 6, 47 (2011). doi:10.1186/1750-1172-6-47
M.F. Rolland-Cachera, T.J. Cole, M. Sempe, J. Tichet, C. Rossignol, A. Charraud, Body mass index variations: centiles from birth to 87 years. Eur. J. Clin. Nutr. 45(1), 13–21 (1991)
H.L. Muller, U. Gebhardt, C. Teske, A. Faldum, I. Zwiener, M. Warmuth-Metz, T. Pietsch, F. Pohl, N. Sorensen, G. Calaminus, Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur. J. Endocrinol. 165(1), 17–24 (2011). doi:10.1530/EJE-11-0158
H.L. Muller, U. Gebhardt, A. Faldum, M. Warmuth-Metz, T. Pietsch, F. Pohl, G. Calaminus, N. Sorensen, Xanthogranuloma, Rathke’s cyst, and childhood craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations. J. Clin. Endocrinol. Metab. 97(11), 3935–3943 (2012). doi:10.1210/jc.2012-2069
C. Pequeux, J.C. Hendrick, M.T. Hagelstein, V. Geenen, J.J. Legros, Novel plasma extraction procedure and development of a specific enzyme-immunoassay of oxytocin: application to clinical and biological investigations of small cell carcinoma of the lung. Scand. J. Clin. Lab. Invest. 61(5), 407–415 (2001)
W.S. Young 3rd, H. Gainer, Transgenesis and the study of expression, cellular targeting and function of oxytocin, vasopressin and their receptors. Neuroendocrinology 78(4), 185–203 (2003). doi:10.1159/000073702
M. Ludwig, N. Sabatier, P.M. Bull, R. Landgraf, G. Dayanithi, G. Leng, Intracellular calcium stores regulate activity-dependent neuropeptide release from dendrites. Nature 418(6893), 85–89 (2002). doi:10.1038/nature00822
D.V. Pow, J.F. Morris, Dendrites of hypothalamic magnocellular neurons release neurohypophysial peptides by exocytosis. Neuroscience 32(2), 435–439 (1989)
D.A. Baribeau, E. Anagnostou, Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front. Neurosci 9, 335 (2015). doi:10.3389/fnins.2015.00335
H.G. Bauer, Endocrine and other clinical manifestations of hypothalamic disease; a survey of 60 cases, with autopsies. J. Clin. Endocrinol. Metab. 14(1), 13–31 (1954). doi:10.1210/jcem-14-1-13
G.J. Morton, D.E. Cummings, D.G. Baskin, G.S. Barsh, M.W. Schwartz, Central nervous system control of food intake and body weight. Nature 443(7109), 289–295 (2006). doi:10.1038/nature05026
J.M. Ho, J.E. Blevins, Coming full circle: contributions of central and peripheral oxytocin actions to energy balance. Endocrinology 154(2), 589–596 (2013). doi:10.1210/en.2012-1751
G. Zhang, H. Bai, H. Zhang, C. Dean, Q. Wu, J. Li, S. Guariglia, Q. Meng, D. Cai, Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron 69(3), 523–535 (2011). doi:10.1016/j.neuron.2010.12.036
G.J. Morton, B.S. Thatcher, R.D. Reidelberger, K. Ogimoto, T. Wolden-Hanson, D.G. Baskin, M.W. Schwartz, J.E. Blevins, Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am. J. Physiol. Endocrinol. Metab. 302(1), E134–144 (2012). doi:10.1152/ajpendo.00296.2011
B.R. Olson, M.D. Drutarosky, M.S. Chow, V.J. Hruby, E.M. Stricker, J.G. Verbalis, Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats. Peptides 12(1), 113–118 (1991)
Y. Wu, E. van Dijk, X. Zhou, Evaluating self- vs. other-owned objects: the modulatory role of oxytocin. Biol. Psychol. 92(2), 179–184 (2013). doi:10.1016/j.biopsycho.2012.11.011
D. Cai, S. Purkayastha, A new horizon: oxytocin as a novel therapeutic option for obesity and diabetes. Drug Discov. Today Dis. Mech. 10(1-2), e63–e68 (2013). doi:10.1016/j.ddmec.2013.05.006
J.E. Blevins, J.M. Ho, Role of oxytocin signaling in the regulation of body weight. Rev. Endocr. Metab. Disord. 14(4), 311–329 (2013). doi:10.1007/s11154-013-9260-x
V. Ott, G. Finlayson, H. Lehnert, B. Heitmann, M. Heinrichs, J. Born, M. Hallschmid, Oxytocin reduces reward-driven food intake in humans. Diabetes 62(10), 3418–3425 (2013). doi:10.2337/db13-0663
W. Qian, T. Zhu, B. Tang, S. Yu, H. Hu, W. Sun, R. Pan, J. Wang, D. Wang, L. Yang, C. Mao, L. Zhou, G. Yuan, Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J. Clin. Endocrinol. Metab. 99(12), 4683–4689 (2014). doi:10.1210/jc.2014-2206
N. Cook, J. Miller, J. Hart, Parent observed neuro-behavioral and pro-social improvements with oxytocin following surgical resection of craniopharyngioma. J. Pediatr. Endocrinol. Metab. (2016) doi:10.1515/jpem-2015-0445. (in press)
R. Sobota, T. Mihara, A. Forrest, R.E. Featherstone, S.J. Siegel, Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism. Behav. Neurosci. 129(4), 389–398 (2015). doi:10.1037/bne0000074
K. Lancaster, C.S. Carter, H. Pournajafi-Nazarloo, T. Karaoli, T.S. Lillard, A. Jack, J.M. Davis, J.P. Morris, J.J. Connelly, Plasma oxytocin explains individual differences in neural substrates of social perception. Front. Hum. Neurosci. 9, 132 (2015). doi:10.3389/fnhum.2015.00132
M.E. McCullough, P.S. Churchland, A.J. Mendez, Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci. Biobehav. Rev 37(8), 1485–1492 (2013). doi:10.1016/j.neubiorev.2013.04.018
I.D. Neumann, R. Landgraf, Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci. 35(11), 649–659 (2012). doi:10.1016/j.tins.2012.08.004
G. Lippi, G.C. Guidi, C. Mattiuzzi, M. Plebani, Preanalytical variability: the dark side of the moon in laboratory testing. Clin. Chem. Lab. Med. 44(4), 358–365 (2006). doi:10.1515/CCLM.2006.073